Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 4927

A water-activated disposable paper battery is presented in a proof-of-principle study in Scientific Reports. The authors suggest that it could be used to power a wide range of low-power, single-use disposable electronics—such as smart labels for tracking objects, environmental sensors and medical diagnostic devices—and minimize their environmental impact.

The , devised by Gustav Nyström and colleagues, is made of at least one cell measuring one centimeter squared and consisting of three inks printed onto a rectangular strip of paper. Sodium chloride salt is dispersed throughout the strip of paper and one of its shorter ends has been dipped in wax. An ink containing graphite flakes, which acts as the positive end of the battery (cathode), is printed onto one of the flat sides of the paper while an ink containing zinc powder, which acts as the negative end of the battery (anode), is printed onto the reverse side of the paper. Additionally, an ink containing graphite flakes and carbon black is printed on both sides of the paper, on top of the other two inks. This ink connects the positive and negative ends of the battery to two wires, which are located at the wax-dipped end of the paper.

When a small amount of water is added, the salts within the paper dissolve and charged ions are released. These ions activate the battery by dispersing through the paper, resulting in zinc in the ink at the negative end of the battery releasing electrons. Attaching the wires to an electrical device closes the circuit so that electrons can be transferred from the negative end—via the graphite and carbon black-containing ink, wires and device—to the positive end (the graphite-containing ink) where they are transferred to oxygen in the surrounding air. These reactions generate an that can be used to power the device.

Read more | >

A research group from the Graduate School of Informatics, Nagoya University, has taken a big step towards creating a neural network with metamemory through a computer-based evolution experiment. Their paper appears in Scientific Reports.

In recent years, there has been rapid progress in designing technology using neural networks that imitate brain circuits. One goal of this field of research is understanding the evolution of metamemory to use it to create artificial intelligence with a human-like mind.

Metamemory is the process by which we ask ourselves whether we remember what we had for dinner yesterday and then use that to decide whether to eat something different tonight. While this may seem like a simple question, answering it involves a complex process. Metamemory is important because it involves a person having knowledge of their own memory capabilities and adjusting their behavior accordingly.

Read more | >

A novel bioremediation technology for cleaning up per-and polyfluoroalkyl substances, or PFAS, chemical pollutants that threaten human health and ecosystem sustainability, has been developed by Texas A&M AgriLife researchers. The material has potential for commercial application for disposing of PFAS, also known as “forever chemicals.”

Published July 28 in Nature Communications, the was a collaboration of Susie Dai, Ph.D., associate professor in the Texas A&M Department of Plant Pathology and Microbiology, and Joshua Yuan, Ph.D., chair and professor in Washington University in St. Louis Department of Energy, Environmental and Chemical Engineering, formerly with the Texas A&M Department of Plant Pathology and Microbiology.

Removing PFAS contamination is a challenge

PFAS are used in many applications such as food wrappers and packaging, dental floss, fire-fighting foam, nonstick cookware, textiles and electronics. These days, PFAS are widely distributed in the environment from manufacturing or from products containing the chemicals, said Dai.

Read more | >

The lab will work in areas such as quantum computing, explainable artificial intelligence (AI) that presents data in a manner that can be understood by humans, and Metaverse, a virtual world where people can connect through their digital avatars.

Tech Mahindra already has 10 Makers Lab across the world and the new unit at Mahindra University will be the 11th facility globally and second in Hyderabad, said the company.

“With the launch of Makers Lab, we will provide many talented and skilled individuals, with the opportunity to progress for a greater cause,” said CP Gurnani, MD & CEO, Tech Mahindra.

Read more | >

IT major Tech Mahindra (TechM) and Mahindra University have signed a memorandum of understanding (MoU) to set up a new ‘Makers Lab’ for research and development. The lab will work in areas such as quantum computing, explainable artificial intelligence (AI) that presents data in a manner that can be understood by humans, and Metaverse, a virtual world where people can connect through their digital avatars.

Tech Mahindra already has 10 Makers Lab across the world and the new unit at Mahindra University will be the 11th facility globally and second in Hyderabad, said the company.

“With the launch of Makers Lab, we will provide many talented and skilled individuals, with the opportunity to progress for a greater cause,” said CP Gurnani, MD & CEO, Tech Mahindra.

Read more | >

I promise you: this post is going to tell a scientifically coherent story that involves all five topics listed in the title. Not one can be omitted.

My story starts with a Zoom talk that the one and only Lenny Susskind delivered for the Simons Institute for Theory of Computing back in May. There followed a panel discussion involving Lenny, Edward Witten, Geoffrey Penington, Umesh Vazirani, and your humble shtetlmaster.

Lenny’s talk led up to a gedankenexperiment involving an observer, Alice, who bravely jumps into a specially-prepared black hole, in order to see the answer to a certain computational problem in her final seconds before being ripped to shreds near the singularity. Drawing on earlier work by Bouland, Fefferman, and Vazirani, Lenny speculated that the computational problem could be exponentially hard even for a (standard) quantum computer. Despite this, Lenny repeatedly insisted—indeed, he asked me again to stress here—that he was not claiming to violate the Quantum Extended Church-Turing Thesis (QECTT), the statement th at all of nature can be efficiently simulated by a standard quantum computer. Instead, he was simply investigating how the QECTT needs to be formulated in order to be a true statement.

Read more | >

Dr. Arye Elfenbein, MD, PhD, is the Co-Founder of Wildtype (https://www.wildtypefoods.com/), a biotechnology company which produces cultured seafood (with a focus on cultivated Pacific salmon) from fish cells, sustainably and cost effectively, with the nutritional benefits, but without common contaminants such as mercury, microplastics, antibiotics, or pesticides, and without relying on commercial fishing or fish farming.

Born in Israel and raised in Australia, Dr. Elfenbein combines his deep passion for medicine and unique childhood connection to the ocean to fuel Wildtype’s health and environmental mission.

After studying at Dartmouth and Kyoto University, attaining a PhD and MD, Dr. Elfenbein began his residency at Yale where he first trained in Internal Medicine before completing training in Cardiology. After residency, he moved to San Francisco to work with Professor Dr. Deepak Srivastava at the revered Gladstone Institutes / UCSF, also known for being the scientific homes of Nobel laureates Dr. Shinya Yamanaka (iPs cells) and Dr. Jennifer Doudna (CRISPR).

During his time at the Gladstone Institutes, Dr. Elfenbein’s research focused on cardiac regeneration following heart attacks. This research inspired him to apply the principles of stem cell biology beyond medicine, and to address the growing problems in our food system.

Continue reading “Dr. Arye Elfenbein, MD, PhD — Co-Founder, Wildtype — Building A Better Food System” | >

Dr. Amber Salzman, Ph.D. is Chief Executive Officer and Director of Epic Bio (https://epic-bio.com/), a fascinating therapeutic epigenome editing startup, developing therapies to modulate gene expression at the level of the epigenome, which just recently emerged from stealth mode with a $55 million funding round.

Dr. Salzman has more than 30 years of experience in the pharmaceuticals industry. Before joining Epic Bio, Dr. Salzman served as the president and CEO of Ohana Biosciences, pioneering the industry’s first sperm biology platform. Before Ohana, she served as the president and CEO of Adverum Biotechnologies and was a co-founder of Annapurna, SAS, where she served as President and CEO before its merger with Avalanche Biotechnologies to become Adverum. In that role, she saw the company’s stock price double.

Dr. Salzman began her career as a member of the GlaxoSmithKline (GSK) research and development executive team, where she was responsible for operations in drug development across multiple therapeutic areas, overseeing global clinical trials with over 30,000 enrolled patients, managing 1,600 employees and a $1.25B budget.

Following her time at GSK, Dr. Salzman served as the CEO of Cardiokine, a pharmaceutical company that developed treatments for the prevention of cardiovascular diseases and saw the successful sale of the company to Cornerstone Therapeutics.

Continue reading “Dr. Amber Salzman, PhD — CEO & Director, Epic Bio — Editing The Epigenome To Treat Complex Diseases” | >